title: Association between long-term kidney graft survival and the presence of pre-transplant cytotoxic anti-HLA and/or non-MHC 'Fc gamma RII blocking' (anti-TLX) alloantibody.
abstract: One hundred kidney graft recipients were analysed retrospectively with regard to the presence of Fc gamma RII (EAI) blocking or cytotoxic HLA antibody induced by pretransplant transfusion. Previous studies suggested that transfusion induces the production of EAI blocking antibody which may have specificity to TLX/CD46/MCP alloantigens. A superior graft survival (65%/9 yr) was found in the presence of EAI alloantibody compared to graft survival in the absence of this antibody (40%/9 yr). Further analysis showed the following survival rates in relation to the combined appearance of HLA cytotoxic and EAI antibody (EAI positive, HLA negative 67%/9 yr; EAI positive, HLA positive 60%/9 yr; EAI negative, HLA positive 0%/9 yr; EAI negative, HLA negative 40%/9 yr). There was striking low graft failure in the first 6 months in patients with EAI antibody. Taking into consideration that the HLA B/DR mismatching grade in all various groups were the same and no considerable difference was found in association to graft survival, the presence or absence of alpha EAI (anti-TLX) antibody solely seems to have superior or additional effect on graft survival as compared to HLA matching.
authors.affiliation: Department of Immunogenetics, National Institute of Haematology and Immunology, Budapest, Hungary.
authors.forename: A
authors.initials: A
authors.lastname: Padányi
authors.forename: E
authors.initials: E
authors.lastname: Gyódi
authors.forename: K
authors.initials: K
authors.lastname: Rajczy
authors.forename: F
authors.initials: F
authors.lastname: Perner
authors.forename: G G
authors.initials: GG
authors.lastname: Petrányi
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000032:analysis; D015703:Antigens, CD / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D006085:Graft Survival / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology*; D015235:HLA-B Antigens / Q000276:immunology; D006684:HLA-DR Antigens / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D007518:Isoantibodies / Q000032:analysis*; D007519:Isoantigens / Q000276:immunology*; D016030:Kidney Transplantation / Q000276:immunology*; D008214:Lymphocytes / Q000276:immunology*; D017452:Receptors, IgG / Q000276:immunology*; D012189:Retrospective Studies; D012397:Rosette Formation
chemical_list: D000888:Antibodies, Anti-Idiotypic; D015703:Antigens, CD; C080568:Fc gamma receptor IIA; D006680:HLA Antigens; D015235:HLA-B Antigens; D006684:HLA-DR Antigens; D007518:Isoantibodies; D007519:Isoantigens; D017452:Receptors, IgG; C055067:trophoblast-lymphocyte cross-reactive antigens